Critical Review: Cadrenal Therapeutics (NASDAQ:CVKD) vs. Adhera Therapeutics (OTCMKTS:ATRX)

Cadrenal Therapeutics (NASDAQ:CVKD) and Adhera Therapeutics (OTCMKTS:ATRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Risk and Volatility

Cadrenal Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 12.21, suggesting that its share price is 1,121% more volatile than the S&P 500.

Earnings and Valuation

This table compares Cadrenal Therapeutics and Adhera Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24 million	($5.63)	-0.88
Adhera Therapeutics	N/A	N/A	N/A	($1.15)	N/A

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Adhera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 26.1% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 28.2% of Adhera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Cadrenal Therapeutics and Adhera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
Adhera Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and target prices for Cadrenal Therapeutics and Adhera Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1	0	1	0	2.00
Adhera Therapeutics	0	0	0	0	0.00

Cadrenal Therapeutics currently has a consensus target price of $13.00, suggesting a potential upside of 161.04%. Given Cadrenal Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Cadrenal Therapeutics is more favorable than Adhera Therapeutics.

Summary

Adhera Therapeutics beats Cadrenal Therapeutics on 5 of the 9 factors compared between the two stocks.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.